A study was performed to establish the effect of A13+ and Fe24 cations on the absorption of ofloxacin when it is administered orally at a dose of 200 mg. The study was carried out with nine volunteers, who each received three treatments (A [200 mg of ofloxacin], B [200 mg of ofloxacin plus 11 g of colloidal aluminum phosphate], and C [200 mg of ofloxacin plus 1,050 mg of FeSO41) according to a Latin square design; the washout period was 1 week. The analytical technique was a microbiological diffusion method. The pharmacokinetic parameters were calculated from the cumulative urinary excretion data and from a sigma-minus plot. The total amount of ofloxacin excreted in urine had a mean value of 163.59 + 22.13 mg when ofloxacin was administered alone, 152.41 ± 18.76 mg when it was administered with Al3+, and 146.49 + 14.85 mg when it was administered with Fe2+. No statistically significant differences were found in the F values (fractions of dose absorbed) obtained with ofloxacin alone and ofloxacin plus Al3+ (P = 0.341). When ofloxacin alone was compared with joint administration with Fe24 the value of F decreased 10.85%; this difference is statistically significant (P = 2.623 X 10-2).
Ofloxacin is included in the fluoroquinolone group together with ciprofloxacin, norfloxacin, pefloxacin, and lomefloxacin, among other drugs. From the qualitative point of view, these compounds have similar kinetic characteristics, although they exhibit important quantitative differences that affect mainly their absorption and metabolism (4, (8) (9) (10) 14) .
It has been reported that the combined administration of agents containing A13+, Mg2", or Fe2" considerably reduces the degree of absorption of some of the quinolones, such as ciprofloxacin (5, 6, 15) , norfloxacin (13, 20) , and pefloxacin (22) . The aim of the present work was to establish whether this kind of interaction occurs in the combination of ofloxacin and A13+ or Fe2+, since there are few data regarding this in the literature and the published data are not comparable. Hoffken et al. (7) have shown that a sizable decrease in the absorption of ofloxacin occurs when it is administered simultaneously with antacids; more recently, Flor et al. (4) have shown that a slight decrease in the absorption of ofloxacin occurs when it is administered 2 h after the administration of a dose of antacid.
MATERIALS AND METHODS
This study was carried out at two levels: in in vitro and in vivo experiments.
In vitro assay. To study the passage of ofloxacin across intestinal membranes, we employed the method described by Wilson and Wiserman (25) with slight modifications. In particular, we injected unreversed intestinal sacs, 5 cm in length, from Wistar rats with 0.5 ml of a solution containing ofloxacin (1 mg/ml) in the presence and in the absence of the Al" cation. The intestinal sac, always made with the fragment of gut corresponding to the first partition after the choledoch, was placed into a glass Erlenmeyer flask containing 25 ml of Krebs-Ringer bicarbonate solution (21) maintained at 37°C.
Each day, the experiment was carried out with two fragments of intestine under identical experimental condi-* Corresponding author. tions; one fragment was used to study the passage of ofloxacin in the absence of Al3", and the other was used to study the passage of the drug in the presence of the cation. Samples were collected from the interior and exterior of the intestinal sacs at previously scheduled times (10, 20, 30 , and 45 min), and the value of the in vitro absorption constant (Ki), together with the total amount absorbed after 45 min (Q,), was calculated. The experiment was repeated with 10 intestinal fragments for each situation (absence or presence of Al3"). The source of Al3+ was KAI(SO4)2. 12H20 (Fluka S.A.), and the concentration of A13+ was 0.43 mg/ml, for a molar concentration ratio of ofloxacin to Al3+ of 3:1.
In vivo assay. The in vivo assay was carried out with nine healthy volunteers of both sexes, with ages between 22 and 32 years and a mean weight (± standard deviation) of 61 ± 12 kg. None of the volunteers had received any medication for at least 1 week prior to the experiments, and all gave consent to participate after being informed of the purposes and nature of the study.
All volunteers received treatment A, which consisted of the oral administration of 200 mg of ofloxacin; treatment B, which comprised the same dose of the quinolone plus 11 g of colloidal aluminum phosphate (Fosfalumina; SeheringPlough); and treatment C, which comprised the same dose of ofloxacin plus 1,050 mg of FeSO4 (two tablets of FeroGradumet; Abbott). The washout period was 1 week. The subjects had fasted for 12 h with water ad libitum before receiving medication and did not eat until 2 h had elapsed since administration. The study was carried out according to a Latin square design (24) . Urine samples were collected over the 33 h after administration of ofloxacin, and the drug concentrations in the urine samples were determined.
Analytical technique. In all cases (samples from the in vitro assay and urine samples), a microbiological plate diffusion method was used (16) , with Bacillus subtilis as the assay organism for the determination of ofloxacin levels. Standard solutions were prepared with urine (from healthy volunteers taken before ofloxacin administration) for analysis of the urine samples and with Krebs-Ringer bicarbonate solution (21) for the samples from the in vitro part of the study. The EFFECTS OF A13+ AND Fe2+ ON OFLOXACIN ABSORPTION concentration ranges were 100 to 5 and 10 to 0.5 jLg/ml, respectively.
This microbiological technique was studied and contrasted with a high-performance liquid chromatography technique that was developed in our laboratory for the measurement of ofloxacin in biological fluids. Statistical comparison of the methods showed that there were no significant differences between the concentrations determined by the two methods (17 The cumulative urinary excretion curves were constructed by graphing the total amounts of ofloxacin excreted in urine against time. The total amount excreted (U,) and the fraction of dose absorbed (F) were calculated. The F value was calculated from the UJ/D ratio, since ofloxacin is sparingly metabolized and almost completely eliminated in an unaltered form through the kidneys (4) . By using the sigmaminus plot (23), the elimination rate constant was calculated.
Statistical analysis. After the normal distribution of the data was checked by the Shapiro-Wilks test (19) , a two-way analysis of variance was performed for statistical compari- is the standard deviation of the parameters compared, at is the level of significance (a = 0.05), and n is number of individuals (n = 9).
RESULTS
The passage of ofloxacin through the membrane of the intestinal sacs occurs through a first-order process whose constant has a mean value (± standard deviation) of (3.22 ± 1.19) x 10-3 and (3.74 ± 1.66) x 10-3 min-' in the absence and presence of Al3+, respectively (Fig. 1) Figure 2 shows the mean curves of urinary excretion of ofloxacin for treatments A, B, and C, and together reveals no statistical differences in the values of F or U,. (P = 0.138 and 0.153, respectively), which means that these differences are not relevant. When ofloxacin is administered with Fe2", the amount absorbed decreases slightly and the value of U,,. is reduced by 10.85%. Statistical comparison of F values for treatments A and C reveals significant differences (P = 2.623 x 10-2); nevertheless, the magnitude of the reduction in the percentage of absorption is not very important from the clinical point of view. These results are conclusive with regard to this hypothesis and clearly show that the oral absorption of ofloxacin is not modified as a result of the simultaneous administration of 11 g of colloidal aluminum phosphate. With 1,050 mg of ferrous sulfate, absorption decreases slightly.
These results should be interpreted with caution; one cannot affirm that ofloxacin does not interact with antacids in any conditions of administration, but it is clear that its absorption is not modified by the administration of a single dose of antacid containing Al3+. In any case, it is clear that its behavior differs significantly from those of other quinolones such as ciprofloxacin, whose absorption is seriously decreased by the coadministration of Al3", Mg2", or Fe2+.
Differences among the few published reports about ofloxacin interaction can be found; Hoffken et al. (7) affirm that ofloxacin oral absorption decreases by 69% when the drug is administered in combination with an antacid containing Al" and Mg2+ (10 oral Accordingly, it is essential to consider the interaction between the quinolone agents and antacid agents containing cations when setting up therapy with these drugs. Taking into account the fact that the antibacterial spectra of the quinolones currently used in clinical practice are similar, a possible alternative would be to use ofloxacin when the patient is simultaneously receiving a nonsystemic antacid agent or ferrous salts. If the etiology of the infective process indicates that another quinolone with which interaction occurs should be used, a dose regimen in which at least 2 h elapse between the administration of the quinolone and the administration of the antacid agent must be followed, as suggested by other authors (11, 12) .
